Taylor & Francis Group
Supplementary figures.docx (931.82 kB)

Supplementary figures: Cytotoxic T lymphocytes targeting a conserved SARS-CoV-2 spike epitope are efficient serial killers

Download (931.82 kB)
posted on 2022-03-17, 13:51 authored by Daniel Meyer, Mohsen Fathi, Lindsey Charley, Laurence Cooper, Navin Varadarajan

Supplementary Figure 1: (A) Multiple sequence alignment of the conserved epitope (DD9) on the spike protein of SARS-CoV-2 variants; YP_009724390 (Wuhan), B.1.617.2 (Delta), B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.1.529 (Omicron). All sequences were downloaded from NCBI and aligned by Clustal Omega. (B) 3D structure of SARS-CoV-2 spike protein (PDB ID 6VYB) highlighted with DD9 peptide in red (Constructed in Jmol: an open-source Java viewer for chemical structures in 3D. http://www.jmol.org/).

Supplementary Figure 2: (A) The distribution of T cells (effector) and target cells (target) in the nanowell array. (B) The Kaplan Meier survival curve of target cells in absence (0E:1T) and presence of one T cell (1E:1T).

Supplementary Figure 3: The percentage of target cell apoptosis in different E:T ratios in a bulk assay for 48 hours (Cytation). All target cells were pre-incubated with peptide for 60 minutes before co-culturing.


NV was supported by the NIH (R01GM143243), CPRIT (RP180466), MRA Established Investigator Award (509800), NSF (1705464), CDMRP (CA160591), and Owens foundation. DDM, NV, MF, LC and LJNC have equity ownership in CellChorus. LJNC receives royalties from Bristol Myers Squibb (via City of Hope National Medical Center) and Immatics (via MD Anderson Cancer Center), holds receipts of intellectual property rights from Sangamo BioSciences, MD Anderson Cancer Center, and Ziopharm Oncology, and also has equity ownership interest in Targazyme, Ziopharm Oncology, Immatics, Secure Transfusion Services, AuraVax Therapeutics, and IterateBio. NV has equity ownership in AuraVax Therapeutics and owns intellectual property rights from UH.